AppDatabaseToolsGuidesMethodology
Home / Public Compound Dataset
Machine-readable public reference data

Halflife Labs public compound dataset

A versioned export of the 44 public compound profiles with stable record IDs, evidence labels, source links, revision dates, and explicit limitations.

Version 2026-06-1344 recordsNot medical advice
Download

JSON dataset · CSV dataset · Methodology. The export excludes dose recommendations. A public reuse license has not been specified; contact Halflife Labs before redistribution.

Dataset scope and limits

Each record preserves the public profile's half-life statement, route, evidence classification, source summary, documented citations, revision date, and scientific-review status. Reported values are not measured individual concentrations. Nonhuman, inferred, estimated, and unresolved values are labeled separately.

Provenance

  • Stable dataset ID: https://halflife-labs.com/data/#compound-dataset
  • Stable record IDs: hlc:<compound-slug>
  • Author: Halflife Labs
  • Scientific review: claimed only where the individual source page documents reviewedBy; reviewer scope is limited on the About page.
  • Revision date: 2026-06-13

Record index

RecordHalf-life statementEvidenceValue classificationSource
5-Amino-1MQ
hlc:5-amino-1mq		 ~5h oral (rat); no human PK data Preclinical, inferred, community, or unresolved source estimate or nonhuman Primary source
AOD-9604
hlc:aod-9604		 ~0.5h (estimate) Preclinical, inferred, community, or unresolved source estimate or nonhuman Primary source
BPC-157
hlc:bpc-157		 ~15 min plasma (rat) Preclinical, inferred, community, or unresolved source estimate or nonhuman Primary source
Cagrilintide
hlc:cagrilintide		 ~168h (7 days) Published human or clinical source reported human or label value Primary source
CJC-1295 (no DAC)
hlc:cjc-1295-no-dac		 ~30 min (community estimate) Preclinical, inferred, community, or unresolved source estimate or nonhuman Primary source
CJC-1295 (with DAC)
hlc:cjc-1295-dac		 ~140–194h (5.8–8.1 days) Published human or clinical source reported human or label value Primary source
DSIP
hlc:dsip		 Reported ~30–40 min after human IV; human SC value unknown Published human or clinical source unknown or unresolved Primary source
Epitalon
hlc:epitalon		 No published human PK data — community estimate Preclinical, inferred, community, or unresolved source unknown or unresolved Primary source
GHK-Cu
hlc:ghk-cu		 Human pharmacokinetic half-life unknown Preclinical, inferred, community, or unresolved source unknown or unresolved Primary source
GHRP-2
hlc:ghrp-2		 ~33 min (β t½ after 1 µg/kg IV) Published human or clinical source reported human or label value Primary source
GHRP-6
hlc:ghrp-6		 Distribution ~8 min; elimination ~2.5h Published human or clinical source reported human or label value Primary source
Gonadorelin
hlc:gonadorelin		 ~2–10 min Published human or clinical source reported human or label value Primary source
Hexarelin
hlc:hexarelin		 ~55 min (human IV) Published human or clinical source reported human or label value Primary source
HGH (Somatropin)
hlc:hgh		 ~3.0–3.8h SC; ~0.4h IV FDA-approved product or prescribing-label source reported human or label value Primary source
IGF-1 / Mecasermin
hlc:igf-1		 ~5.8h SC FDA-approved product or prescribing-label source reported human or label value Primary source
IGF-1 LR3
hlc:igf-1-lr3		 ~20–30h (community/industry estimate) Preclinical, inferred, community, or unresolved source estimate or nonhuman Primary source
Insulin — Degludec
hlc:insulin-degludec		 ~25h at steady state; duration >42h FDA-approved product or prescribing-label source estimate or nonhuman Primary source
Insulin — Detemir
hlc:insulin-detemir		 ~5–7h SC; duration up to 24h FDA-approved product or prescribing-label source estimate or nonhuman Primary source
Insulin — Glargine
hlc:insulin-glargine		 Duration ~24h; peakless — depot-driven kinetics FDA-approved product or prescribing-label source estimate or nonhuman Primary source
Insulin — NPH
hlc:insulin-nph		 Onset 1–3h; duration up to 24h FDA-approved product or prescribing-label source estimate or nonhuman Primary source
Insulin — Rapid Acting
hlc:insulin-rapid		 ~42–81 min SC; duration ~5h FDA-approved product or prescribing-label source estimate or nonhuman Primary source
Insulin — Regular
hlc:insulin-regular		 Duration ~8h SC; ~4–6 min IV elimination FDA-approved product or prescribing-label source estimate or nonhuman Primary source
Ipamorelin
hlc:ipamorelin		 ~2h (animal estimate; human PK unknown) Preclinical, inferred, community, or unresolved source unknown or unresolved Primary source
KPV
hlc:kpv		 Short (no formal human data) Preclinical, inferred, community, or unresolved source unknown or unresolved Primary source
LL-37
hlc:ll-37		 Minutes (proteolytic degradation) Preclinical, inferred, community, or unresolved source estimate or nonhuman Primary source
MK-677 / Ibutamoren
hlc:mk-677		 ~24h Published human or clinical source reported human or label value Primary source
MOTS-c
hlc:mots-c		 ~1–4h (preclinical estimate) Preclinical, inferred, community, or unresolved source estimate or nonhuman Primary source
NAD+ (Injectable)
hlc:nad-injectable		 No formal human plasma t½ published Preclinical, inferred, community, or unresolved source unknown or unresolved Primary source
Oxytocin
hlc:oxytocin		 ~1–6 min FDA-approved product or prescribing-label source reported human or label value Primary source
PEG-MGF
hlc:peg-mgf		 ~24h (PEGylated; native MGF ~5–7 min) Preclinical, inferred, community, or unresolved source estimate or nonhuman Primary source
PT-141 / Bremelanotide
hlc:pt-141		 ~2.7h SC (range 1.9–4.0h) FDA-approved product or prescribing-label source reported human or label value Primary source
Retatrutide
hlc:retatrutide		 ~144h (6 days) Published human or clinical source reported human or label value Primary source
Selank
hlc:selank		 ~7–10 min plasma (rat) Preclinical, inferred, community, or unresolved source estimate or nonhuman Primary source
Semaglutide
hlc:semaglutide		 ~168h (7 days) FDA-approved product or prescribing-label source reported human or label value Primary source
Semax
hlc:semax		 ~2–5 min plasma (rat); 12–24h functional effects Preclinical, inferred, community, or unresolved source estimate or nonhuman Primary source
Sermorelin
hlc:sermorelin		 ~11–12 min Published human or clinical source reported human or label value Primary source
SLU-PP-332
hlc:slu-pp-332		 ~3.5h (mouse) Preclinical, inferred, community, or unresolved source estimate or nonhuman Primary source
SS-31 / Elamipretide
hlc:ss-31		 ~2h (preclinical); ~4h SC (human trial data) FDA-approved product or prescribing-label source estimate or nonhuman Primary source
TB-500
hlc:tb-500		 Minutes (equine data) Preclinical, inferred, community, or unresolved source estimate or nonhuman Primary source
Tesamorelin
hlc:tesamorelin		 ~8 min (Egrifta SV) / ~11 min (Egrifta WR) SC FDA-approved product or prescribing-label source reported human or label value Primary source
Testosterone Cypionate
hlc:testosterone-cypionate		 ~192h (8 days) IM FDA-approved product or prescribing-label source reported human or label value Primary source
Testosterone Enanthate
hlc:testosterone-enanthate		 ~108h (4.5 days) IM FDA-approved product or prescribing-label source reported human or label value Primary source
Thymosin Alpha-1
hlc:thymosin-alpha-1		 ~2h SC Published human or clinical source reported human or label value Primary source
Tirzepatide
hlc:tirzepatide		 ~120h (5 days) FDA-approved product or prescribing-label source reported human or label value Primary source